[Barbexaclone in the treatment of cerebral dysrhythmia].
Forty two patients (22 adults and 20 children or adolescents) with cerebral dysrithmia were included in a therapeutic trial using barbexaclone: 28 patients suffered from grand mal crises, 2 had associated GM and petit mal and 12 showed disturbances of behaviour without clinical crises. The patients were observed from 6 to 13 months. Four patients failed to complete the trial due to various side effects; 25 patients with GM and 11 with behaviour disturbances showed a very good response; two patients with associated petit mal failed to show any improvement. Side effects such as insomnia and irritability were seen in 8 patients. The authors concluded that barbexaclone is an excellent therapeutic agent in the treatment of grand mal and in patients with behaviour disturbances without convulsive crises.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D004832:Epilepsy, Absence / Q000188:drug therapy*; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011437:Propylamines / Q000031:analogs & derivatives / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy*
D011437:Propylamines; C011019:barbexaclone; D010634:Phenobarbital
Barbexaclone no tratamento das disritmias cerebrais.